Cephalosporin Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-02　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 21.87 Bn
2033 年預估規模: USD 23.65 Bn
年複合成長率 CAGR: 3.76%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-02頁數 151報告編號 CMI2893

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Cephalosporin Drugs Market, By Generation (First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization’s (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area. Market Dynamics Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015. However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations. Key features of the study • This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2026, considering 2018 as the base year • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global cephalosporin drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies • Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics • The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts Market Segmentation • By Generation o First-generation Cephalosporin o Second-generation Cephalosporin o Third-generation Cephalosporin o Fourth-generation Cephalosporin o Fifth-generation Cephalosporin • By Type o Branded Cephalosporin Drugs o Generic Cephalosporin Drugs • By Formulation o Oral  Tablets  Capsules  Liquid o Injection • By Indication o Respiratory Tract Infection o Skin Infection o Ear Infection o Bacterial Infection o Urinary Tract Infection o Sexually Transmitted Infection o Sinus Infection o Surgical Prophylaxis o Others  Meningitis  Acute Abdomen Infection  Pelvic infection • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Merck & Co. Inc. o GlaxoSmithKline plc. o Pfizer Inc. o Allergan plc. o Abbott Laboratories o Basilea Pharmaceutica Ltd. o Sanofi S.A. o Hoffmann-La Roche AG o Lupin Limited o Teva Pharmaceutical Industries Ltd. o Braun Melsungen AG.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Generation  Market Snippet, By Type  Market Snippet, By Formulation  Market Snippet, By Indication  Market Snippet, By Distribution Channel  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Drivers o Restraints o PEST Analysis o PORTER’s Five Forces Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global Cephalosporin Drugs Market, By Generation, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o First-Generation Cephalosporin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Second-Generation Cephalosporin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Third-Generation Cephalosporin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Fourth-Generation Cephalosporin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Fifth-Generation Cephalosporin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 5. Global Cephalosporin Drugs Market, By Type, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Branded Cephalosporin Drugs  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Generic Cephalosporin Drugs  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 6. Global Cephalosporin Drugs Market, By Formulation, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Oral  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Tablets  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Capsules  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Liquid  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Injection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 7. Global Cephalosporin Drugs Market, By Indication, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Respiratory Tract Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Skin Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Ear Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Bacterial Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Urinary Tract Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Sexually Transmitted Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Sinus Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Surgical Prophylaxis  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Others  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Meningitis  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Acute Abdomen Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Pelvic Infection  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 8. Global Cephalosporin Drugs Market, By Distribution Channel, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Retail Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Online Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 9. Global Cephalosporin Drugs Market, By Region, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.S. o Canada o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033  Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)  Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o South Africa o North Africa o Central Africa 10. Competitive Landscape o Heat Map Analysis  Market Share Analysis (3x3 Matrix)  Company Profiles  Merck & Co. Inc.  Company Overview  Product Type Portfolio  Recent Developments/Updates o GlaxoSmithKline plc.  Company Overview  Product Type Portfolio  Recent Developments/Updates  Pfizer Inc.  Company Overview  Product Type Portfolio  Recent Developments/Updates o Allergan plc.  Company Overview  Product Type Portfolio  Recent Developments/Updates  Abbott Laboratories  Company Overview  Product Type Portfolio  Recent Developments/Updates o Basilea Pharmaceutica Ltd.  Company Overview  Product Type Portfolio  Recent Developments/Updates  Sanofi S.A.  Company Overview  Product Type Portfolio  Recent Developments/Updates o F. Hoffmann-La Roche AG  Company Overview  Product Type Portfolio  Recent Developments/Updates  Lupin Limited  Company Overview  Product Type Portfolio  Recent Developments/Updates o Teva Pharmaceutical Industries Ltd.  Company Overview  Product Type Portfolio  Recent Developments/Updates  B. Braun Melsungen AG.  Company Overview  Product Type Portfolio  Recent Developments/Updates 11. Analyst Recommendation o Wheel of Fortune o Analyst View o Coherent Opportunity Map 12. Section o References o Research Methodology o About Us and Sales Contact

提及公司

Merck & Co. Inc.GlaxoSmithKline plc.Pfizer Inc.Allergan plc.Abbott LaboratoriesBasilea Pharmaceutica Ltd.Sanofi S.A.Hoffmann-La Roche AGLupin LimitedTeva Pharmaceutical Industries Ltd.Braun Melsungen AG.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們